16型人乳头瘤病毒衣壳蛋白在真核细胞中的表达

为了构建HPV16型晚期蛋白重组杆状病毒,并使其在昆虫细胞中获得高效表达.首先构建2株重组杆状病毒转移质粒,分别携带人乳头瘤病毒晚期基因L1及L1和L2,再用线性化的杆状病毒DNA与该重组杆状病毒转移质粒共转染sf9昆虫细胞进行同源重组,获得2株重组杆状病毒.经鉴定该重组病毒中有目的基因存在且可表达所编码的L1或L2晚期蛋白.结果表明HPV16型晚期蛋白在昆虫细胞中获得成功表达,为HPV16型预防性基因工程亚单位疫苗的研制和诊断试剂的研究开发奠定了基础.     

HPV18L1基因重组DNA构建及其对小鼠免疫的实验研究

人类乳头瘤病毒（HUmanPaPillornarus,HPV）能引起人类皮肤、粘膜的乳头状瘤或疣,其中HPV18等型别与宫颈癌的发生发展密切相关。由于HPV18不能进行体外培养,政制备疫苗仅能依靠基因丁程疫苗。HPV基因功能区由早期基因区（E区）、晚期基因区动区）和调节区组成。L区包括LI和M,LI编码病毒的本要农壳蛋白,能刺激机体产生保护性抗体。为此LI基因是构建基因工程疫苗的理想目的基因。采用PCR法从HPV18－IZoltJ22质粒中扩增HPV18LI基因,分别与2个真核表达载体重组,构建了HPV18LI－PCDNA3和HPV18LI一po重级质粒。将提…     

表达人乳头瘤病毒58型L1、L2壳蛋白的非复制型重组痘苗病毒疫苗株的构建

采用PCR定点突变方法,对HPV581L1基因中痘苗病毒早期基因转录终止信号TTTTTNT结构进行修饰,并保留氨基酸不变.选用非复制型重组痘苗病毒为载体,将修饰的L1基因1.5kb和L2基因1.4kb分别插入痘苗病毒表达载体pJSD的7.5k和H6早期启动子之后,使之与非复制型重组痘苗病毒在TK区重组.经单斑筛选纯化,获得共表达HPV58L1、L2晚期蛋白的非复制型重组痘苗病毒疫苗实验株.该病毒在CEF细胞上连续传至第15代,经斑点杂交分析,重组痘苗病毒基因组中有L1和L2基因插入;经Western blot检测,重组病毒能稳定表达HPV581L1及L2蛋白.此结果为HPV58型非复制型重组痘苗病毒疫苗人用株的研究打下了基础.     

毕赤酵母STE13基因敲除对GGH表达及其生物活性的影响

目的:重组毕赤酵母GS115/pPIC9K-GGH表达的人胰高血糖素样肽-1-人血清白蛋白融合蛋白[(GLP-1 A2G)2-HSA,GGH]的细胞活性测评结果显示生物活性较低,这可能与其表达过程中蛋白降解有一定关联.通过对毕赤酵母GS115 STE13基因的敲除,获得一株完整表达蛋白GGH的毕赤酵母宿主,并进一步提高其表达产物GGH的生物活性.方法:采用基于PCR技术介导的Cre-Loxp系统重组技术成功敲除宿主菌GS115的STE13基因,得到一株STE13缺陷型菌株GS115/D13,并通过细胞活性测评系统检测GS115/D13表达产物GGH的生物活性.结果:通过对STE13基因缺陷型菌株GS115/D13与出发菌株GS115/W发酵表达对比,显示GS115/D13菌株表达融合蛋白GGH生物活性有明显提升,且表达量提高了25.8％,两菌株生长无明显差异.结论:STE13基因的敲除成功缓解了GGH表达过程中的降解问题,并相对出发菌株GS115/W大幅度提高了蛋白生物活性.     

腺病毒载体介导密码子优化型HPV 16 L1基因在哺乳动物细胞中的高效表达及病毒样颗粒的装配

为研究重组腺病毒载体作为HPV16预防性疫苗的可行性,构建了含密码子优化型HPV 16 L1基因的重组腺病毒,并对优化基因在哺乳动物细胞中的表达进行研究。首先按照哺乳动物密码子偏好对野生型HPV16 L1基因进行改造并合成优化基因,命名为mod.HPV16L1。将mod.HPV16L1基因克隆到穿梭质粒PDC316上,与骨架质粒共转染293细胞,在细胞内包装重组腺病毒rAd-mod.HPV16L1。用免疫印迹法检测病毒感染的293T细胞中HPV16L1蛋白的表达。通过Optiprep密度梯度超速离心法纯化HPV16 L1病毒样颗粒(VLPs)。用磷钨酸负染,在电子显微镜下观察HPV16 L1蛋白自我装配形成的VLPs。结果显示,重组腺病毒载体可介导mod.HPV16 L1基因在哺乳动物细胞内的高效表达,L1蛋白可自我装配形成VLPs。     

人乳头瘤病毒16亚型L1蛋白在多形汉逊酵母中的优化表达

为了实现人乳头瘤病毒(Humanpa pillomavirus,HPV)16亚型衣壳蛋白L1在多形汉逊酵母(Hansenula polymorpha)中的高效表达,根据L1蛋白的氨基酸序列及多形汉逊酵母的密码子偏爱性,对L1蛋白的编码序列进行优化设计,合成了完整的编码序列,命名为HPV16L1。以甲醇诱导型启动子MOXp和终止子AOXTT为表达调控元件,以尿嘧啶合成相关基因URA3为筛选标记,构建了HPV16L1的重组表达质粒pYMOXU-HPV16。用SacII酶切质粒pYMOXU-HPV16使其线性化,电转化多形汉逊酵母菌株H-ura3,依据营养缺陷互补筛选重组菌株。通过PCR扩增及HPV16L1蛋白表达量分析表明已获得稳定高表达L1蛋白的重组汉逊酵母菌株HP-U-16L。摇瓶发酵条件的初步优化表明,以YPM(pH7.0)为基础培养基进行诱导培养,控制接种量使初始培养液OD600为1.0,每隔12h补加甲醇至终浓度为1%(V/V),37oC、200r/min条件下诱导培养72h后,HPV16L1蛋白的最高表达量为78.6mg/L。本研究为多形汉逊酵母源HPV16L1疫苗的研制奠定了基础。     

HPV18晚期蛋白L1在毕赤酵母菌中的表达及鉴定

目的:用毕赤酵母胞内表达载体构建含人乳头瘤病毒18型(HPV18)L1基因质粒,诱导表达并进行鉴定。方法:按照毕赤酵母密码子偏爱性原则,合成全长L1基因,然后克隆到pAO819表达载体上,在体外分别构建含一个拷贝和二个拷贝的L1基因载体。线形化后转化到GS115酵母细胞,经G418抗性筛选,获高拷贝重组子并经甲醇诱导表达,表达产物采用化学发光Western blot鉴定,一抗为抗HPV18L1蛋白鼠抗血清。结果:在55kDa处有诱导蛋白免疫印迹出现,并在电镜下观察到HPV18的病毒样颗粒(VLPs),证明该表达系统能表达出HPV18 L1蛋白。结论:本实验构建的毕赤酵母表达菌株,可经甲醇诱导表达HPV18L1晚期蛋白,为进一步研制人乳头瘤病毒18型基因工程疫苗打下基础。     

HPV16重组减毒沙门氏菌表达质粒的构建及其诱导免疫

将人乳头瘤病毒(Human papillomavirus,HPV)16 L1E7基因插入携带霍乱毒素基因的pET-CTA2B载体,获得HPV16L1E7与CTA2B融合表达质粒pET-L1E7CTA2B.在此基础上,通过PCR基因克隆技术,将pET载体的T7启动子与pTETnir15载体的大肠杆菌硝酸盐还原酶基因B启动子nirB进行分割重组,将nirB启动子的厌氧调控元件和启动子基本元件FNR-TATA盒与T7启动子的核糖体结合位点(SD)序列融合,形成nirB-T7杂合启动子.最后获得HPV16重组减毒沙门氏细菌疫苗表达载体pNir-16L1E7CTA2B,并进一步构建对照质粒pNir-16L1E7.Western blot结果证实以上质粒nirB-T7杂合启动子能够在沙门氏细菌中表达L1E7融合蛋白.口服免疫接种小鼠可成功诱导小鼠生殖道产生HPV16特异性粘膜免疫,且霍乱毒素CTA2B可以增强粘膜免疫诱导能力,为开发廉价有效的HPV16预防性疫苗打下了基础.     

pTracer—CMV／HPV16L1的大量制备及其转染真核细胞的电镜结果

人乳头瘤病毒（HumanPaPillornairus,HPV）16型（HPV16）是引起宫颈癌的主要因素,但目前尚缺乏有效的预防手段。在动物实验中已经证实HPV16晚期基因LI的产物具有诱导产生中和抗体及细胞免疫的表位,诱导产生的免疫可抵抗再次感染,故LI基因是制备核酸疫苗的最佳侯选基因。从本室构建的pCRZ．1－HPV16LI重组质粒上将LI基因片段克隆至美核表达载体pTracer－CMVL,在国内首次构建成pTracer—CMV－HPV16LI真核表达质料。现将实验结果报道如下。1材料与方法三二五材料1．1．1质粒与细胞①pTracer－CMV－HPV16LI,本室构建…     

HPV16重组减毒沙门氏菌表达质粒的构建及其诱导免疫

将人乳头瘤病毒(Human papillomavirus,HPV)16 L1E7基因插入携带霍乱毒素基因的pET CTA2B载体,获得HPV16L1E7与CTA2B融合表达质粒pET L1E7CTA2B。在此基础上,通过PCR基因克隆技术,将pET载体的T7启动子与pTETnir15载体的大肠杆菌硝酸盐还原酶基因B启动子nirB进行分割重组,将nirB启动子的厌氧调控元件和启动子基本元件FNR TATA盒与T7 启动子的核糖体结合位点(SD)序列融合,形成nirB T7 杂合启动子。最后获得HPV16重组减毒沙门氏细菌疫苗表达载体pNir 16L1E7CTA2B,并进一步构建对照质粒pNir 16L1E7。Western blot结果证实以上质粒nirB T7杂合启动子能够在沙门氏细菌中表达L1E7 融合蛋白。口服免疫接种小鼠可成功诱导小鼠生殖道产生HPV16 特异性粘膜免疫,且霍乱毒素CTA2B可以增强粘膜免疫诱导能力,为开发廉价有效的HPV16预防性疫苗打下了基础。     

Heterogeneous Nuclear Ribonucleoprotein C Proteins Interact with the Human Papillomavirus Type 16 (HPV16) Early 3′-Untranslated Region and Alleviate Suppression of HPV16 Late L1 mRNA Splicing

In order to identify cellular factors that regulate human papillomavirus type 16 (HPV16) gene expression, cervical cancer cells permissive for HPV16 late gene expression were identified and characterized. These cells either contained a novel spliced variant of the L1 mRNAs that bypassed the suppressed HPV16 late, 5′-splice site SD3632; produced elevated levels of RNA-binding proteins SRSF1 (ASF/SF2), SRSF9 (SRp30c), and HuR that are known to regulate HPV16 late gene expression; or were shown by a gene expression array analysis to overexpress the RALYL RNA-binding protein of the heterogeneous nuclear ribonucleoprotein C (hnRNP C) family. Overexpression of RALYL or hnRNP C1 induced HPV16 late gene expression from HPV16 subgenomic plasmids and from episomal forms of the full-length HPV16 genome. This induction was dependent on the HPV16 early untranslated region. Binding of hnRNP C1 to the HPV16 early, untranslated region activated HPV16 late 5′-splice site SD3632 and resulted in production of HPV16 L1 mRNAs. Our results suggested that hnRNP C1 controls HPV16 late gene expression.     

HPV16l1基因的克隆及其在真核细胞中的表达

克隆并表达人乳头瘤病毒16型(HPV16)晚期基因l1,以期为研制防治宫颈癌的DNA疫苗奠定基础。本实验采用PCR方法从质粒p16L1BN1中获得HPV16l1基因片段,利用基因重组技术,将其克隆至含巨细胞病毒(CMV)启动子的真核表达载体中,核酸序列鉴定HPV16l1基因真核表达质粒构建成功,再用脂质体介导基因转染7721人肝癌细胞。转化阳性细胞经SDS-PAGE显示在分子量大约为55kDa的位置出现一条特异性条带,与HPV16L1分子量大小相符。表达产物经Western blotting分析:能与HPV16L1单克隆抗体特异结合。真核表达质粒pcDNA3-HPV16L1构建成功并能在真核细胞7721中有效表达,为下一步进行动物DNA免疫实验奠定了基础。     

Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants

To develop a plant expression system for the production of the human papillomavirus type 16 (HPV16) vaccine, we investigated whether the HPV16 L1 protein can be expressed in tobacco plants and whether it can be used as the cheapest form of edible vaccine. The HPV16 L1 coding sequence was amplified by PCR using specific primers from the plasmid pGEM-T-HPV16 containing the template sequence, and subcloned into the intermediate vector pUCmT and binary vector pBI121 consecutively to obtain the plant expression plasmid pBI-L1. The T-DNA regions of the pBI-L1 binary vector contained the constitutive Cauliflower mosaic virus (CaMV) 35S promoter and the neomycin phosphotransferase npt Ⅱ gene, which allowed the selection of transformed plants using kanamycin. The tobacco plants were transformed by cocultivating them, using the leaf disc method, with Agrobacterium tumefaciens LBA4404, which harbored the plant expression plasmid. The regenerated transgenic tobacco plants were selected using kanamycin, and confirmed by PCR. The results of the Southern blot assay also showed that the HPV16 L1 gene was integrated stably into the genome of the transformed tobacco plants. The Western blot analysis showed that the transformed tobacco leaves could express the HPV 16 L1 protein. Furthermore, it was demonstrated by ELISA assay that the expressed protein accounted for 0.034%-0.076% of the total soluble leaf protein, was able to form 55nm virus-like particles compatible with HPV virus-like particle (VLP), and induced mouse erythrocyte hemagglutination in vitro. The present results indicate that the HPV 16 L1 protein can be expressed in transgenic tobacco plants and the expressed protein possesses the natural features of the HPV16 L1 protein, implying that the HPV16 L1 transgenic plants can be potentially used as an edible vaccine.     

HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation

We provide evidence that the human papillomavirus (HPV) E2 protein regulates HPV late gene expression. High levels of E2 caused a read-through at the early polyadenylation signal pAE into the late region of the HPV genome, thereby inducing expression of L1 and L2 mRNAs. This is a conserved property of E2 of both mucosal and cutaneous HPV types. Induction could be reversed by high levels of HPV-16 E1 protein, or by the polyadenylation factor CPSF30. HPV-16 E2 inhibited polyadenylation in vitro by preventing the assembly of the CPSF complex. Both the N-terminal and hinge domains of E2 were required for induction of HPV late gene expression in transfected cells as well as for inhibition of polyadenylation in vitro. Finally, overexpression of HPV-16 E2 induced late gene expression from a full-length genomic clone of HPV-16. We speculate that the accumulation of high levels of E2 during the viral life cycle, not only turns off the expression of the pro-mitotic viral E6 and E7 genes, but also induces the expression of the late HPV genes L1 and L2.     

利用重组HPV16L1抗原检测宫颈癌抗L1或VLP抗体的对比

为了评价重组大肠杆菌表达的HPV16L1蛋白和重组腺病毒表达的HPV16L1 VLP两种抗原在检测宫颈癌抗 16L1或VLP抗体及在宫颈癌血清学诊断意义上的差别 ,应用PCR技术从宫颈癌组织的DNA中扩增出全长15 35bp的HPV16L1基因片段 ,克隆至 pUC18 T载体中 ,进行DNA测序鉴定。然后 ,将HPV16L1基因克隆至pGEX 2T表达载体中 ,并诱导表达HPV16L1融合蛋白 ,分子量为 83kD ,能被HPV16L1单克隆抗体所识别。经GST柱层析法纯化后 ,与重组腺病毒表达的HPV16L1 VLP分别经酶联免疫吸附 (ELISA)法检测 12份宫颈癌患者和 35份献血员血清。 12例宫颈癌血清标本中 ,抗HPV16L1蛋白的抗体阳性率为 7例 (占 5 8.3% ) ;抗HPV16L1 VLP的抗体阳性率为 8例 (占 6 6 .7% )。经大肠杆菌表达的重组抗原HPV16L1检测为HPV16抗体IgG( )的 7份患者血清 ,利用HPV16L1 VLP试剂盒检测均阳性 ;经大肠杆菌表达的重组抗原检测为HPV16抗体IgG( )的 5份患者血清 ,利用HPV16L1 VLP试剂盒检测有 1份阳性。两者对HPV16抗体的阳性检出率并无显著差异 (P >0 .0 5 )。本实验结果说明HPV16与宫颈癌高度相关 ,利用大肠杆菌表达的重组抗原HPV16L1和HPV16L1 VLP重组抗原检测抗体的敏感性并不受影响。利用重组抗原HPV16L1对宫颈癌的抗体进行定性、定量分析有助于该疾病     

密码子优化型HPV16L1基因在两种昆虫细胞中的表达

目的:提高16型人乳头瘤病毒（HPV16）L1基因在杆状病毒昆虫细胞中的表达水平,为研制预防性HPV疫苗奠定基础。方法:根据昆虫细胞密码子偏性对野生型HPV16L1基因进行改造,利用Bac-to-Bac表达系统获得重组杆状病毒,感染昆虫细胞Sf9和High Five。Western blot鉴定表达产物;电镜下观察病毒样颗粒形成。利用ELISA法评价HPV16L1基因的优化效果,探讨L1蛋白表达的最佳条件。结果:在相对分子质量56kDa处出现HPV16L1的特异性条带;电镜下可见病毒样颗粒在昆虫细胞的核内形成;优化型HPV16L1基因的表达水平显著高于野生型。High Five细胞表达的最佳条件为MOI=10,表达时相72h,其L1蛋白表达量至少比Sf9细胞高3倍。结论:密码子优化技术确实能够促进HPV16L1蛋白的高效表达,而High Five细胞表现出的显著优势尤其值得关注。